Oncology Central

Targeting antiapoptotic and proapoptotic proteins for novel chronic lymphocytic leukemia therapeutics


Deficiency in the apoptotic program is one of the hallmarks of chronic lymphocytic leukemia. Defective apoptosis mainly results from the constitutive activation of survival pathways, which leads to the transcription and overexpression of antiapoptotic factors. The latter include proteins of the Bcl-2 family and members of the IAP family.

To view restricted content, please:

Leave A Comment